Intravitreal delivery of an ELOVL2 product reduces age-related molecular changes in the retina and restores visual function.

Editor’s note: This is a developing news story. Please check back soon for updates. The FDA granted fast track designation to SAR446597, an intravitreal gene therapy for the treatment of geographic atrophy due to age-related macular degeneration, according to a press release from Sanofi. The one-time injection is designed to target and inhibit two components of the complement pathway: C1s in the classical pathway and factor Bb in the alternative pathway. “This dual-targeting approach potentially offers clinical advantages by providing sustained complement suppression within the

Evaluating acute anatomical changes of Bruch’s membrane opening and optic nerve head pit depth in patients receiving 0.05cc of anti-VEGF intravitreal injections

Purpose: This literature review synthetizes current evidence on the timing and efficacy of dexamethasone intravitreal injections for diabetic macular edema in patients undergoing cataract surgery, particularly phacoemulsification, to determine the optimal timing for improved outcome. Methods: A systematic review of the literature was conducted across key databases to identify peer-reviewed studies, clinical trials, and meta-analyses addressing dexamethasone injections administered pre-, intra-, and postoperatively for diabetic macular edema in the context of cataract surgery. Studies were selected based on relevance to timing, visual outcomes, and inflammation control, with a focus on comparative efficacy. Results: The findings suggest that timely dexamethasone injections can substantially reduce inflammation and enhance visual recovery for patients with diabetic macular edema undergoing cataract surgery. Studies indicate that preoperative injections may effectively dampen the inflammatory response triggered by surgical trauma, potentially preserving retinal integrity, whereas intraoperative and postoperative administrations contribute to sustained anti-inflammatory effects during the recovery phase. Comparative studies also highlight dexamethasone's advantages over other anti-inflammatory treatments, such as NSAIDs, particularly in preventing cystoid macular edema. Notably, there was considerable variation in dosage and timing across studies, underscoring the need for standardized treatment protocols. Conclusion: Dexamethasone intravitreal injections offer a valuable intervention for managing diabetic macular edema in diabetic patients undergoing cataract surgery, with optimal timing playing a crucial role in maximizing therapeutic benefits. Preoperative injections appear to be particularly beneficial in reducing the risk of postoperative inflammatory complications. Further research should focus on developing comprehensive guidelines for timing and dosage to standardize treatment and improve patient outcomes in this high-risk population.

We utilized the Longitudinal Health Insurance Database wh...

Povidone-iodine (PI) is the gold standard for pre-intravitreal injection ocular antisepsis. Chlorhexidine (CHX) is an emerging alternative with less ocular irritation. This meta-analysis aims to evaluate post-injection endophthalmitis rates with the use…

Purpose of review Many ocular neovascular diseases, including diabetic retinopathy (DR) and diabetic macular edema (DME), are significant complications that can worsen during pregnancy, posing risks to vision. Antivascular endothelial growth factor (anti-VEGF) agents represent the mainstay of DR and DME treatment in nonpregnant populations. However, their use in pregnant populations remain controversial due to concerns over fetal safety. This review explores the available literature on anti-VEGF use during pregnancy, evaluating maternal and fetal outcomes, and incorporating lessons learned from their recent use in treating retinopathy of prematurity (ROP). Recent findings Although human data on the safety of anti-VEGF agents during pregnancy remain limited, available studies suggest that systemic absorption is minimal, and concerns regarding potential effects on fetal angiogenesis largely theoretical. Case reports and retrospective studies have not consistently demonstrated harm. Furthermore, several studies examining long-term systemic effects of anti-VEGF use in treating premature infants with ROP reveal no association with adverse neurodevelopmental outcomes when compared to untreated ROP or ROP treated with laser photocoagulation alone. Summary While the use of anti-VEGF agents in pregnancy remains controversial, recent evidence suggests they should not be categorically excluded as a treatment option. Until more causal studies emerge, treatment decisions should be individualized, balancing disease severity, maternal visual function, and fetal safety.

Geographic atrophy (GA) is the late-stage of non-exudative age-related macular degeneration (AMD) and a major cause of irreversible vision loss among the elderly worldwide.1,2 While GA typically appears as a late manifestation of non-exudative AMD, GA can be present in eyes with exudative AMD as well.3,4 It is defined as well-circumscribed regions within the macula characterized by the degeneration of photoreceptors, the retinal pigment epithelium (RPE), and the choriocapillaris (CC),5,6 and these regions enlarge over time and eventually expand to encompass most of the macula.

KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Ramiro Ribeiro, MD, PhD, of EyePoint Pharmaceuticals, discusses Duravyu, a vorolanib intravitreal insert. According to Ribeiro, in the DAVIO 2 trial, Duravyu for wet age-related macular…

LAS VEGAS — In this Healio Video Perspective from Clinical Trials at the Summit, Arshad M. Khanani, MD, MA, FASRS, highlights first-time results of PER-001 intravitreal implant in diabetic retinopathy. PER-001 (Perfuse Therapeutics), an endothelin antagonist, was delivered at low and high doses and compared with control, showing structure improvements in macular ischemia, leakage and microaneurysms. Additionally, in a glaucoma program, patients experienced improved OCT retinal nerve fiber layer and blood flow to the optic nerve. “In terms of function, we actually saw improvement in

A pseudophakic patient was found to have a chronic rhegmatogenous retinal detachment, posterior vitreous detachment, hypotony, and serous choroidal detachments (A), a presentation that can prevent safe trocar insertion and complicate vitrectomy surgery during retinal detachment repair. A presurgical intravitreal gas injection was performed through the superior pars plana. One day later, the intraocular pressure was normalized, and the choroidal detachments were nearly resolved (B). A single retinal break at the 2:30 position was easily visualized, and the patient proceeded with uncomplicated vitrectomy surgery later that day.

.